Entero Healthcare Solutions FY26 Annual Earnings Summary

Closure of two announced acquisitions delayed due to drug license site outage, impacting revenue recognition timing.

Management acknowledged evolving integration approach (more aggressive now), but past slower integration may have caused inefficiencies.

Management plans to slow acquisitions for 2-3 quarters to integrate, but cost synergies may take longer, pressuring margins.

Medtech acquisitions bring higher gross margins but also higher employee and marketing costs, which could limit net margin expansion.

Effective tax rate of 13-18% is low due to carry-forward losses; once exhausted, tax rate could normalize to 25%, impacting PAT.

Minority interest spiked to 38% of PAT in Q4 due to abnormal subsidiary profit; guided to normalize to ~25%, but could remain lumpy.

Seven acquisitions closed in FY26, including three in medtech; integration risks and retention of key personnel are critical.

Finance costs rose as IPO funds were deployed; management expects stable near-term costs but sequential decline only over 2-3 years.

Analyst raised concern about Amazon and Zepto entering pharmacy; management downplayed risk citing range, AOV, and prescription challenges.

Article reported termination of exclusive distribution with Servier; management clarified it was modified to allow direct supply, but exclusivity for marketing retained.

Analyst raised concern that PharmEasy's recovery could increase competition for acquisition targets, though management downplayed the risk.

Organic growth multiplier vs IPM has compressed to ~1.4x from ~1.7x as IPM growth accelerated; any IPM slowdown could pressure organic growth.